Subcutaneous BRIUMVI Shows Positive Phase 1 Data, Could Double Market Opportunity for TG Therapeutics
TGTX sits 46% above its 52-week low of $25.28.
Summary
TG Therapeutics reported positive Phase 1 results for a subcutaneous formulation of its key multiple sclerosis drug, BRIUMVI. The data demonstrated favorable pharmacokinetics, pharmacodynamics, and a well-tolerated safety profile, supporting a quarterly dosing regimen. This follows the completion of enrollment for the Phase 3 trial of this formulation in April, and an 8-K filing today confirming these results. Management believes a self-administered, at-home, quarterly subcutaneous option could nearly double BRIUMVI's addressable market. Top-line Phase 3 data is anticipated by year-end 2026 or early 2027, with potential approval in 2028.
At the time of this announcement, TGTX was trading at $36.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $25.28 to $44.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.